Clinical trial · no report yet · Phase 2
NCT03194542
A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence
- NCT03194542 ↗
- Completed
- Celgene
- 7 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 4 | |
| YouTube | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase-2 Study To Determine Efficacy and Safety of Luspatercept in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With or Without Red Blood Cell-Transfusion Dependence
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Primary Myelofibrosis; Anemia
- Interventions
- Luspatercept
- Arms
- Luspatercept in subjects with MPN-associated myelofibrosis · Experimental
- Enrollment
- 95
- Primary outcomes
- The Number of Participants With Anemia Responses Over Any 84-Day Period During the Primary Treatment Period
- Sponsor
- Celgene
- Start
- Nov 15, 2017
- Primary completion
- Jul 18, 2022
- Results posted
- Yes
- Registry record
- NCT03194542 · updated Aug 24, 2023
Publications
linked from the registry- Gerds AT, Harrison C, Kiladjian JJ, Mesa R, Vannucchi AM, Komrokji R, Bose P, Kremyanskaya M, Mead AJ, Gotlib J, Rose S, Sanabria F, Marsousi N, Giuseppi AC, Jiang H, Palmer JM, McCaul K, Ribrag V, Passamonti F. Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis. Blood Adv. 2024 Sep 10;8(17):4511-4522. doi: 10.1182/bloodadvances.2024012939. PubMed 38820422